Betaliq Inc.
Innovating glaucoma treatments



About us
Betaliq, Inc. is a clinical-stage pharmaceutical company dedicated to transforming glaucoma treatment. By leveraging cutting-edge technology and patient-centric innovation, we aim to address significant unmet needs in eye care and enhance the quality of life for millions worldwide.
Founded in 2018 through a strategic collaboration between BLP Management Group and Novaliq GmbH, Betaliq is redefining topical ophthalmic therapies with a strong focus on safety, efficacy, and innovation. Through this partnership, we hold exclusive rights to Novaliq’s proprietary EyeSol® technology – a water-free drug delivery platform designed to optimize treatment outcomes – for glaucoma therapies. With a vision for expansion, Betaliq is well-positioned to build a portfolio of Glaucoma therapies and to expand into other indications within general ophthalmology and specialty eye care through partnerships.
Our lead drug candidate, BTQ1902, is a timolol suspension formulated with EyeSol®. Following positive Phase 2a data, we are advancing towards Phase 3 clinical trial, bringing us closer to providing an effective and well-tolerated treatment option for glaucoma patients.
Since our inception, Betaliq has built a strong foundation for success, attracting investor confidence and securing key funding milestones. In 2019, we completed an $8 million Series A funding round, led by Brookline Capital Markets.
Our virtual management model has allowed us to efficiently allocate resources, drive innovation, and remain agile as we approach critical milestones, including the completion of Phase 2 as well as the planned Phase 3 trial for BTQ1902.
Glaucoma
Glaucoma is a growing global health challenge and market opportunity
Glaucoma is a leading cause of irreversible blindness worldwide, affecting over 80 million people as of 2020, with numbers projected to exceed 111 million by 2040. Characterized by progressive damage to the optic nerve over time caused from backup of fluid in the eye leading to elevated pressure, called intraocular pressure (IOP), glaucoma remains asymptomatic until advanced stages, underscoring the need for early diagnosis and effective treatment solutions.

Despite the availability of various treatments – including eye drops, laser therapy, and surgical interventions – current options often suffer from limitations such as poor patient adherence, side effects, and incomplete IOP control.

Our commitment to advancing glaucoma therapies
Our pharmaceutical pipeline is focused on addressing the most pressing gaps in glaucoma care. Through novel formulations based on EyeSol®, we are dedicated to improving patient outcomes and enhancing quality of life. With a strong commitment to research and development, strategic partnerships, and operational expertise, we are positioned at the forefront of the next wave of glaucoma treatment solutions.
Our pharmaceutical pipeline is focused on addressing the most pressing gaps in glaucoma care. Through novel formulations based on EyeSol®, we are dedicated to improving patient outcomes and enhancing quality of life. With a strong commitment to research and development, strategic partnerships, and operational expertise, we are positioned at the forefront of the next wave of glaucoma treatment solutions.
Technology
Betaliq’s programs are built on EyeSol®, the worldwide first and only water-free technology for ophthalmic products licensed from Novaliq. EyeSol® addresses the limitations of traditional water-based eye drops and offers improved therapeutic outcomes for a range of eye conditions.
The challenge with traditional water-based eye drops
Water is often the main ingredient in eye drops, serving as a base for other components. These water-based eye drops dispense drops of 40–50 µL, far exceeding the eye’s capacity, leading to spillover and loss of medication. Additionally, the natural surface tension of water and the outer lipid layer of the tear film limit drug spreading on the ocular surface. Moreover, water-based eye drops trigger the eye’s defense mechanisms, causing rapid blinking and tear secretion, further reducing drug retention. All these factors reduce the retention time and contribute to a relatively low bioavailability of traditional topical ophthalmic medications, which is reported to be between 1-10%.
EyeSol®: A New Standard in Ophthalmic Drug Delivery
By addressing these challenges, EyeSol® redefines topical ophthalmic treatments, ensuring longer retention, better absorption, and improved patient outcomes.


Key features of EyeSol®
-
Extended Residual Time: Significantly prolongs the time the formulation remains on the eye, increasing from minutes to hours.
-
High Bioavailability: Enhances the absorption of active pharmaceutical ingredients (APIs) for improved therapeutic effects.
-
Excellent Tolerability and Safety: Demonstrates a strong safety profile with minimal adverse reactions.
-
Minimized Systemic Exposure: The small drop size reduces systemic absorption, enhancing patient safety.
-
Preservative-free: EyeSol®‘s water-free formulation eliminates the need for preservatives, minimizing irritation and adverse effects.
-
Ocular Surface Beneficial: Supports the health and integrity of the ocular surface.
EyeSol® is clinically validated and safe tested in more than 2,500 patients. It is physically, chemically, and physiologically inert, undergoes no catabolism or metabolism and is highly biocompatibility with no bioaccumulation.
EyeSol® technology has been successfully utilized in a range of products that have received FDA and EMA approvals, as well as CE certification, including:
- MIEBO© (perfluorohexyloctane ophthalmic solution)
- VEVYE© (cyclosporine ophthalmic solution) 0.1%
- VEVIZYE© (ciclosporin 0.1% eye drops solution)
- NovaTears©/EvoTears©
- NovaTears©/EvoTears©+Omega-3
Pipeline
Our goal is to establish a comprehensive pipeline of next-generation topical drugs based on our proprietary EyeSol® technology.
DLQ01
Segment | Product Code | Product Rights | Preclinical | Phase II | Phase III | NDA Review | Market |
---|---|---|---|---|---|---|---|
Elevated Intraocular Pressure (Glaucoma) | BTQ1902 (timolol 0.5% suspension in perfluorohexyloctane) |
Global |
|
completed
|
1 single trial
|
||
BTQ2301 (latanoprost solution in EyeSol® |
Global |
|
|
||||
accelerated development |
|||||||
BTQ2302 (timolol & latanoprost combination) |
Global |
|
|
|
|||
BTQ1902
BTQ1902 ophthalmic suspension (timolol in perfluorohexyloctane) 0.5% is our lead clinical product in development for the treatment of elevated intraocular pressure in patients with primary open angle glaucoma or ocular hypertension.
BTQ1902 contains timolol maleate 0.5% suspended in EyeSol®. Utilizing EyeSol® as the vehicle for ophthalmic suspension allows development of the product as a non-preserved suspension in a multi-dose bottle, minimizing tolerability and ocular irritation issues due to the lack of other excipients such as preservatives or phosphates.
Key Advantages of BTQ1902 over existing timolol therapies
-
Less drug exposure due to >60% smaller drop size at equal efficacy (clinically demonstrated)
-
Water-free, non-preserved in multi-dose bottle
-
More drops per volume allows to develop multi-month supply in a single bottle
-
Vehicle with proven efficacy & safety in dry eye disease
-
Novel suspension with long-lasting patent protection

The Phase 2 clinical trial results for BTQ1902 ophthalmic suspension (timolol in perfluorohexyloctane) 0.5% in patients with open-angle glaucoma or ocular hypertension revealed a clinically meaningful reduction in intraocular pressure (IOP). BTQ1902 not only met the study’s objective of statistical non-inferiority but also confirmed its efficacy and safety profile are comparable to the established standard of Timolol 0.5%. Furthermore, participants tolerated BTQ1902 well, demonstrating an excellent safety profile throughout the trial.

Following these promising results, the FDA confirmed that a single Phase 3 trial will be sufficient for New Drug Application (NDA) submission, accelerating the path toward potential approval.
Team
Management and Board of Directors

Barry Butler, MBA
Chief Executive Officer
Barry Butler is a seasoned pharmaceutical executive with over 35 years in leadership roles across the industry. Barry served as Global Category Leader for Pharmaceuticals at Bausch & Lomb, founder and CEO of Sirion Therapeutics, and Managing Partner of Point Guard Partners prior to becoming Founder and CEO of Betaliq. Barry holds a Bachelor of Science Degree in Finance from The University of Alabama and an MBA degree from City University of Seattle.

Oliver Schlüter, PhD
Chief Financial Officer
Dr. Schlüter besides his position at Betaliq is CFO & Managing Director of Novaliq since 2015. Prior to this Dr. Schlüter was CFO of CureVac GmbH from 2010 to 2015 where he was instrumental in the transformation of a 70 employee R&D-driven company to a 170-employee customer-centric and value-focused corporation that entered into several strategic partnerships with in-house cGMP-manufacturing. During his time at CureVac the company’s value increased more than tenfold and reached unicorn status with a value of more than $1bn. During the past 15 years in Biotech/Pharma he secured more than $400m cash for the organizations he served. Dr. Schlüter has 25+ years of professional experience within the fields of Finance and Life Sciences. He holds a PhD in computational finance and also studied business administration.

Ronil Patel, MS
Chief Operating Officer
Mr. Ronil Patel is, in parallel to his position at Betaliq, the Chief Business Officer at RevOpsis Therapeutics, bringing over 15 years of experience in medical research, biotech R&D, and global business development. Active in ophthalmology since 2012, he has successfully managed multiple clinical-stage assets leading to FDA approval and commercialization in the US. His expertise includes in/out-licensing of clinical-stage assets and he has held executive roles in both public and private sectors, contributing to over $100 million in funding and exit deals exceeding $500 million. Mr. Patel earned a Master of Science in Biotechnology from the Florida Institute of Technology.

Christian Roesky, PhD
Director (Chair)
Dr. Roesky is CEO & Managing Director of Novaliq since November 2016. Previously, Dr. Roesky was General Manager for the D-A-CH region of Bausch + Lomb GmbH in Berlin; Commercial Director Central Europe of Abbott’s Diagnostics Division, General Manager and speaker of the German Country Management Board of Abbott GmbH & Co. KG in Wiesbaden from 2013-2015; and, General Manager of Alcon Germany & Austria (Novartis) from 2009-2013. He studied chemistry in Bonn and Freiberg, both in Germany, and was awarded his Ph.D. with honors from the Technical University of Freiberg in Germany.

A. Joseph Rudick, MD
Director
Dr. Rudick, a renowned LASIK surgeon and dry eye specialist with over 30 years of experience, provides comprehensive eye care in New York, including routine exams, cosmetic enhancements, and treatment of eyelid disorders. He is affiliated with prestigious institutions such as the New York Eye and Ear Infirmary and Manhattan Eye and Ear Hospital. A graduate with highest honors from the Perelman School of Medicine at the University of Pennsylvania, he completed his residency at The Manhattan Eye, Ear and Throat Hospital and is a founding member of the National Glaucoma Trust. Dr. Rudick continues to deliver exceptional care at his two Manhattan offices.

Christopher A. Jones, DPHIL
Director
Dr. Christopher A. Jones is an Assistant Professor in the Department of Surgery at The Larner College of Medicine. As an accomplished health economist, he specializes in clinical applications and global health initiatives. He earned his PhD in Health Economics and MS in Human Biology from the University of Oxford, following a Bachelor of Science from the University of Michigan, Ann Arbor. Additionally, Dr. Jones completed his postdoctoral training as a NICE Fellow at the Royal Institute of Psychiatry and University College London and served as a Faculty Research Associate at Johns Hopkins University.
Contact
Headquarters
Betaliq Inc.
905 E. Martin Luther King Jr. Dr.
Suite 240
Tarpon Springs, FL 34689
Betaliq Inc.
905 E. Martin Luther King Jr.
Dr.
Suite 240
Tarpon Springs, FL 34689